To the full analysis
Kopin stock: growth
KOPNKopin reported $38.47M in revenue for fiscal 2025, down 23.6% on the prior year, down 0.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
−3.2%
per year from 2006 to 2025, per share −7.8%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | −0.8% | 1.8% | −3.2% |
| Revenue per share | −14.3% | −7.8% | −7.8% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $71.09M | −$2.15M | −$6.98M |
| 2007 | $98.15M | −$6.56M | −$11.77M |
| 2008 | $114.81M | $2.59M | $8.34M |
| 2009 | $114.65M | $19.44M | $19.67M |
| 2010 | $120.39M | $8.93M | −$1.92M |
| 2011 | $131.14M | $3.6M | $12.12M |
| 2012 | $34.64M | −$18.36M | −$6.04M |
| 2013 | $22.9M | −$25.11M | −$19.64M |
| 2014 | $31.81M | −$28.21M | −$21.09M |
| 2015 | $32.05M | −$14.69M | −$18.04M |
| 2016 | $22.64M | −$23.37M | −$26.57M |
| 2017 | $27.84M | −$25.24M | −$28.71M |
| 2018 | $24.47M | −$34.53M | −$29.35M |
| 2019 | $29.52M | −$29.51M | −$21.2M |
| 2020 | $40.13M | −$4.41M | −$4.96M |
| 2021 | $45.67M | −$13.43M | −$11.78M |
| 2022 | $47.4M | −$19.33M | −$18.52M |
| 2023 | $40.39M | −$19.75M | −$16.21M |
| 2024 | $50.34M | −$43.88M | −$15.04M |
| 2025 | $38.47M | $2.61M | −$16.98M |
Revenue by segment
How Kopin Corp. makes its money and how that has shifted. Names are as the company reports them.
- Defense76%
- Research and Development12%
- Industrial8%
- Grant2%
- Medical2%
- License and Royalties1%
- Other< 1%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|
| Defense | $22.62M | $41.25M | $29.36M | 76.3% |
| Research and Development | $13.46M | $6M | $4.59M | 11.9% |
| Industrial | $2.74M | $2.2M | $3.03M | 7.9% |
| Grant | no data | no data | $858K | 2.2% |
| Medical | no data | $103K | $594K | 1.5% |
| License and Royalties | $1M | $442K | $410K | 1.1% |
| Other | $586.18K | $0 | $0 | 0% |
| Total revenue | $40.39M | $50.34M | $38.47M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 27 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 9 Oct 2026)
- Valuation signal Overvalued since 10 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.